Cobra Biomanufacturing announces the award of two European patents, further strengthening its patent portfolio in the area of plasmid DNA manufacture
One patent (EP 1080179) covers Cobra's Riboclear system of novel cell lines engineered specifically for the synthesis of plasmid DNA at lower cost and higher quality and the other (EP 880585) a method for purifying plasmid DNA at scale.
The market for DNA medicines and vaccines is set to grow to in excess of $4 billion within ten years.
These technologies address issues of scalability required for commercialisation and the rigorous quality standards required by the regulatory authorities.
Cobra's leading position in plasmid DNA and the manufacture of other high value, high potency biopharmaceutical products is maintained by continued innovation and investment in novel manufacturing technologies.
David Thatcher, chief executive of Cobra, said: "Cobra provides DNA manufacturing services which are second to none, our ability to offer this service is dependent on our commitment to innovation and the development of technology led manufacturing solutions".
"Along with our ORT and ORT-VAC technologies, the grant of these patents in Europe is another important step forward in consolidating Cobra's position as the leading manufacturer of plasmid DNA medicines and vaccines."
